<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02964481</url>
  </required_header>
  <id_info>
    <org_study_id>2015-1749</org_study_id>
    <nct_id>NCT02964481</nct_id>
  </id_info>
  <brief_title>Malignant Hyperthermia Registry and Genetic Testing</brief_title>
  <official_title>Donation of Blood for Genetic Testing With Clinical Data From the North American Malignant Hyperthermia Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to to determine the penetrance of known and probable pathogenic&#xD;
      variants in genes and the factors that contribute to penetrance in a population of children&#xD;
      and adults in the United States exposed to Malignant Hyperthermia (MH) trigger agents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to determine how genetic mutations and variants in combination&#xD;
      with non-genetic factors influence risk for MH in children who had general anesthesia with&#xD;
      triggering agents and develop reliable predictive MH risk algorithms. Rationale: Once the&#xD;
      factors responsible for MH risk are determined, it will be possible to better predict risk&#xD;
      and develop better individualization of anesthetics such as tailored selection of intravenous&#xD;
      anesthetics, regional anesthesia and avoidance of all triggering agents. The long-term goal&#xD;
      is to tailor and improve safety of anesthetic and clinical care and to reduce mortality,&#xD;
      morbidity and cost of care due to MH with right anesthetics and muscle relaxants for&#xD;
      endotracheal intubations for an individual child.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of funding to enroll additional participants&#xD;
  </why_stopped>
  <start_date type="Actual">August 18, 2015</start_date>
  <completion_date type="Actual">February 28, 2017</completion_date>
  <primary_completion_date type="Actual">February 28, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genetic comparison of MH phenotype subjects to that of the CHCT negative control subjects.</measure>
    <time_frame>Within data collection period (5 years total).</time_frame>
    <description>MHS subjects and CHCT negative controls recruited from the North American MH Registry will have whole genome sequencing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genomic factors that influence Malignant Hyperthermia.</measure>
    <time_frame>Within data collection period (5 years total).</time_frame>
    <description>A Batesian inference algorithm based on multiple genetic risk factors assessed from DNA data collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induced pluripotent stem cells will be used for functional testing and gene editing</measure>
    <time_frame>Indefinite - dependent on funding</time_frame>
    <description>Induced pluripotent stem cells will be made for future in-vitro analysis</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">64</enrollment>
  <condition>Malignant Hyperthermia</condition>
  <arm_group>
    <arm_group_label>Malignant Hyperthermia Phenotype cases</arm_group_label>
    <description>Samples from persons who identify as having the malignant hyperthermia phenotype by the North American MH Registry (NAMHR)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caffeine Halothane Contracture Test negative controls</arm_group_label>
    <description>Controls who had negative Caffeine Halothane Contracture Test (CHCT) from North American MH Registry (NAMHR)</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Whole exome sequencing</intervention_name>
    <description>DNA sequencing of protein coding sections of all genes</description>
    <arm_group_label>Caffeine Halothane Contracture Test negative controls</arm_group_label>
    <arm_group_label>Malignant Hyperthermia Phenotype cases</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be used to extract DNA for genotyping, pyrosequencing and pluripotent stem&#xD;
      cells.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with documented MH clinical presentation and CHCT negative controls from NAMHR&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any English speaking person registered at NAHMR who has had a positive clinical&#xD;
             manifestation of Malignant Hyperthermia&#xD;
&#xD;
          -  Any person with a positive Caffeine Halothane Contracture probTest (CHCT) or a close&#xD;
             relative of a person that had these.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any person who has NOT had a positive clinical manifestation of Malignant Hyperthermia&#xD;
&#xD;
          -  Any person with a positive Caffeine Halothane Contracture Test (CHCT) or NOT a close&#xD;
             relative of a person that had these. Non-English speaking registrants will be&#xD;
             excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sadhasivam S, Brandom BW, Henker RA, McAuliffe JJ. Bayesian modeling to predict malignant hyperthermia susceptibility and pathogenicity of RYR1, CACNA1S and STAC3 variants. Pharmacogenomics. 2019 Sep;20(14):989-1003. doi: 10.2217/pgs-2019-0055.</citation>
    <PMID>31559918</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 29, 2016</study_first_submitted>
  <study_first_submitted_qc>November 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2016</study_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malignant</keyword>
  <keyword>genetics</keyword>
  <keyword>RYR1</keyword>
  <keyword>CAC-NA1S</keyword>
  <keyword>hyperthermia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperthermia</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Malignant Hyperthermia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

